Vallourec has signed a new €750 million multi-currency revolving credit facility (RCF) to replace its previous credit lines, improving its financial structure to align with an investment-grade profile. The new five-year credit line, with options to extend, offers better terms and lower financing costs, supporting the group's general funding needs. Coordinated by BNP Paribas and Natixis CIB, the facility involves 13 international banks, reflecting strong lender confidence. This refinancing marks a significant step in strengthening Vallourec's financial strategy and market position.
Vallourec's new €750 million multi-currency revolving credit facility marks a key financial restructuring step. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Nov 06, 2026 13:11 WIB: out of 135 priced US stocks, 38 rose and 95 fell. Notable movers include FPS at USD 18.90 with a -15.78% change, ROK at USD 381.79 down -14.03%, and FCEL at USD 9.08 down -13.85%.
Norwegian oil and gas company DNO ASA announced its shares will trade ex-dividend starting November 6, 2026. Shareholders on record as of November 9 will receive a dividend of NOK 0.375 per share, payable around November 17. This dividend reflects th...
Vallourec has signed a new €750 million multicurrency revolving credit facility (RCF) to replace its previous credit lines, improving its financial structure with better terms and lower costs. The five-year facility, coordinated by BNP Paribas and Na...
The 2026 Global Health Congress in New York gathered over 625 healthcare leaders from 25 countries to discuss innovation, equity, and investment in healthcare. The event featured 350+ startup applications in its Healthcare Shark Tank competition, cro...
Ambarella, an edge AI semiconductor company, announced its third quarter fiscal year 2027 earnings conference call will be held on November 24, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report after the market closes that...
Molecular Partners presented new preclinical data for MP0632, a next-gen T cell engager designed to target solid tumors expressing both MSLN and EpCAM. The data show potent tumor cell killing with a favorable safety profile, sparing healthy tissues t...
